A Transformative Biomarker for Alzheimer's Disease
Discover the power of pTau217, the leading diagnostic biomarker for Alzheimer's disease. Unlock the potential of this commercially available assay and join the fight against Alzheimer's today.
The ALZpath pTau217 Assay
Highly Sensitive Assay: Analytical lower limit of quantification (LLOQ): 0.02 pg/mL; limit of detection (LOD): 0.0052-0.0074 pg/mL
Matrix: Plasma and cerebrospinal fluid (CSF)
Testing Options: Provide samples for analysis or receive assay kits for analysis in your laboratory
How to order ALZpath pTau217 Assay
We have enhanced the manufacturing and distribution of our assay by partnering with Quanterix. Contact us to start an order for
assay kits or sample analysis.
Exploring Applications of the ALZpath pTau217 Assay:
Insights from Research Studies
Sleep Quality and pTau217
University of Rhode Island
Price et al. explored the relationship between sleep quality and pTau217 in older adults with mild cognitive impairment (MCI) and mild Alzheimer's Disease (AD). They found that poorer sleep quality correlated with increased pTau217 levels, suggesting a link between sleep and tau pathology.
pTau217 as an Early Plasma Marker for Alzheimer's Dementia
Luca Kleineida et al.
German Center for Neurodegenerative Diseases
Kleineida et al. investigated the capacity for pTau217 to predict Alzheimer's dementia in older primary care patients. Their findings demonstrated that elevated pTau217 is strongly associated with conversion to Alzheimer's dementia up to eight years later, surpassing the performance of other biomarkers for AD.
Detection of pTau217 in Tear Fluid
Guglielmo Di Molfetta et al.
University of Gothenburg
Di Molfetta et al. detected pTau217 in tear fluid, highlighting the potential of tear fluid as a non-invasive biofluid for biomarker assessment in neurodegenerative disorders.
pTau217 in Clinical Trials of Alzheimer's Disease in Down Syndrome
Nicholas Ashton et al.
Universitat Autònoma de Barcelona
Ashton et al. demonstrate the importance of biomarkers for diagnosis of Alzheimer's disease (AD) in individuals with Down syndrome, as measured in plasma and from a finger prick. Their results highlight the applications of pTau217 in clinical practice and clinical trials, particularly in the Down syndrome community.